In July of last year, the company said it was discontinuing development of the compound, telcagepant, after looking at all its trial data.
WSJ: Fresh Target in Hunt for a Migraine Cure
2.
Merck also announced it had canceled a mid-stage study of its migraine drug telcagepant, viewed as promising, because of elevated levels of liver enzymes in study participants.
FORBES: Earnings
3.
Peter Kim, Merck's head of research and development, said on the company's conference call that the study for migraine prevention was "exploratory" and used a different dosing schedule than other telcagepant trials.